NO20054018L - Intranasal formulering av rotigotin - Google Patents

Intranasal formulering av rotigotin

Info

Publication number: NO20054018L
Authority: NO; Norway
Prior art keywords: rotigotine; intranasal formulation; intranasal; moisturizing; cyclodextrin
Prior art date: 2003-12-23

Application number

NO20054018A

Other languages

English (en)

Norwegian (no)

Inventor

Robert Kraemer

Original Assignee

Sanol Arznei Schwarz Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-23

Filing date

2005-08-30

Publication date

2005-08-30

2005-08-30 Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh

2005-08-30 Publication of NO20054018L publication Critical patent/NO20054018L/no

Links

KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title abstract 2
229960003179 rotigotine Drugs 0.000 title abstract 2
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 abstract 1
229940043377 alpha-cyclodextrin Drugs 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
230000003020 moisturizing effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20054018A 2003-12-23 2005-08-30 Intranasal formulering av rotigotin NO20054018L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03029680A EP1547592A1 (en)	2003-12-23	2003-12-23	Intranasal formulation of rotigotine
PCT/EP2004/014626 WO2005063236A1 (en)	2003-12-23	2004-12-22	Intranasal formulation of rotigotine

Publications (1)

Publication Number	Publication Date
NO20054018L true NO20054018L (no)	2005-08-30

Family

ID=34530709

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054018A NO20054018L (no)	2003-12-23	2005-08-30	Intranasal formulering av rotigotin

Country Status (27)

Country	Link
US (1)	US7683040B2 (is)
EP (2)	EP1547592A1 (is)
JP (1)	JP4430067B2 (is)
KR (1)	KR100718760B1 (is)
CN (1)	CN100374112C (is)
AT (1)	ATE326961T1 (is)
AU (1)	AU2004308641B2 (is)
BR (1)	BRPI0407845A (is)
CA (1)	CA2516400C (is)
CY (1)	CY1105131T1 (is)
DE (1)	DE602004000982T2 (is)
DK (1)	DK1605932T3 (is)
EA (1)	EA008005B1 (is)
ES (1)	ES2262122T3 (is)
HR (1)	HRP20060240T3 (is)
IL (1)	IL170297A (is)
IS (1)	IS2310B (is)
MX (1)	MXPA05008909A (is)
NO (1)	NO20054018L (is)
NZ (1)	NZ541875A (is)
PL (1)	PL1605932T3 (is)
PT (1)	PT1605932E (is)
RS (1)	RS50534B (is)
SI (1)	SI1605932T1 (is)
UA (1)	UA79196C2 (is)
WO (1)	WO2005063236A1 (is)
ZA (1)	ZA200506550B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19814084B4 (de) *	1998-03-30	2005-12-22	Lts Lohmann Therapie-Systeme Ag	D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de)	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
US20040048779A1 (en) *	2002-05-06	2004-03-11	Erwin Schollmayer	Use of rotigotine for treating the restless leg syndrome
US8246979B2 (en) *	2002-07-30	2012-08-21	Ucb Pharma Gmbh	Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) *	2002-07-30	2012-07-03	Ucb Pharma Gmbh	Hot-melt TTS for administering rotigotine
US8246980B2 (en)	2002-07-30	2012-08-21	Ucb Pharma Gmbh	Transdermal delivery system
DE10234673B4 (de) *	2002-07-30	2007-08-16	Schwarz Pharma Ag	Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DK1426049T3 (da)	2002-12-02	2005-08-22	Sanol Arznei Schwarz Gmbh	Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10261696A1 (de)	2002-12-30	2004-07-15	Schwarz Pharma Ag	Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) *	2003-07-26	2007-07-05	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de)	2003-12-18	2005-07-28	Schwarz Pharma Ag	(S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en)	2003-12-23	2005-06-29	Schwarz Pharma Ag	Intranasal formulation of rotigotine
DE10361258A1 (de) *	2003-12-24	2005-07-28	Schwarz Pharma Ag	Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) *	2004-02-20	2005-09-08	Schwarz Pharma Ag	Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) *	2004-03-24	2006-07-06	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) *	2006-06-22	2013-04-11	Ucb Pharma Gmbh	經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) *	2007-05-04	2008-11-05	Schwarz Pharma Ag	Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
PT2215072E (pt)	2007-11-28	2015-10-14	Ucb Pharma Gmbh	Forma polimórfica de rotigotina
US8580801B2 (en)	2008-07-23	2013-11-12	Robert I. Henkin	Phosphodiesterase inhibitor treatment
EP2281559A1 (en)	2009-06-26	2011-02-09	UCB Pharma GmbH	Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CA2767068C (en)	2009-12-22	2016-09-27	Ucb Pharma Gmbh	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
EP2559435A1 (en)	2011-08-19	2013-02-20	UCB Pharma GmbH	Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2013075822A1 (en)	2011-11-22	2013-05-30	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermal therapeutic system (tts) with rotigotine
DE102012013421A1 (de)	2012-07-03	2014-01-09	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermales therapeutisches System (TTS) mit Rotigotin
DE102012013439A1 (de)	2012-07-03	2014-01-23	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
CN103768043B (zh) *	2012-10-22	2015-12-09	苏州药明康德新药开发股份有限公司	采用羟丙基-β-环糊精配制四氢化萘类化合物均一稳定溶液的方法
TW201431570A (zh)	2012-11-22	2014-08-16	Ucb Pharma Gmbh	用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CA2916183C (en)	2013-07-03	2022-03-29	Lts Lohmann Therapie-Systeme Ag	Transdermal therapeutic system with electronic component
EP3108245B1 (en)	2014-02-18	2020-07-22	Robert I. Henkin	Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
WO2015177204A1 (en)	2014-05-20	2015-11-26	Lts Lohmann Therapie-Systeme Ag	Transdermal delivery system containing rotigotine
CA2948221C (en)	2014-05-20	2022-11-22	Lts Lohmann Therapie-Systeme Ag	Transdermal delivery system including an interface mediator
WO2015177209A1 (en)	2014-05-20	2015-11-26	Lts Lohmann Therapie-Systeme Ag	Method for adjusting the release of active agent in a transdermal delivery system
US9956201B2 (en)	2014-07-21	2018-05-01	Spriaso Llc	Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
CN110917125B (zh) *	2020-01-02	2022-08-12	安徽中医药大学	一种罗替戈汀鼻用胶束温敏凝胶的制备方法
WO2023133463A1 (en) *	2022-01-06	2023-07-13	Cyrano Therapeutics, Inc.	Improved nasal administration of parkinson's therapeutics
CN120053353A (zh) *	2024-05-31	2025-05-30	纳索菲德(上海)制药技术有限公司	一种巴氯芬鼻脑递释组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5108991A (en) *	1975-06-19	1992-04-28	Whitby Research, Inc.	Vehicle composition containing 1-substituted azacycloalkan-2-ones
US5218113A (en) *	1986-01-31	1993-06-08	Whitby Research, Inc.	N-substituted thiolactams
US4992422A (en) *	1986-01-31	1991-02-12	Whitby Research, Inc.	Compositions comprising 1-substituted azacycloalkanes
JPS63502282A (ja) *	1986-01-31	1988-09-01	ホイットビ−・リサ−チ・インコ−ポレ−テッド	１−置換アザシクロアルカン類より成る組成物とその用法
US4755535A (en) *	1986-04-23	1988-07-05	Nelson Research & Development Co.	Compositions comprising 1-substituted azacycloalkenes
US5073544A (en)	1986-08-15	1991-12-17	Whitby, Inc.	Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US4902676A (en) *	1986-09-29	1990-02-20	Nelson Research & Development Co.	Compositions comprising N,N-dialkylalkanamides
DE3868866D1 (de) *	1987-11-20	1992-04-09	Erba Carlo Spa	Ergolinderivate mit antiparkinsonwirkung.
US5472946A (en) *	1988-04-08	1995-12-05	Peck; James V.	Transdermal penetration enhancers
US5073844A (en) *	1991-01-11	1991-12-17	The Annlouise Partnership	Lighted baggage piece
US6086905A (en) *	1991-03-21	2000-07-11	Peck; James V.	Topical compositions useful as skin penetration barriers
US5308625A (en) *	1992-09-02	1994-05-03	Cygnus Therapeutic Systems	Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en)	1992-10-05	1999-11-23	Cygnus, Inc.	Two-phase matrix for sustained release drug delivery device
DE69434304T2 (de) *	1993-03-26	2005-12-29	Merkus, Franciscus Wilhelmus H.M.	Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
GB9324018D0 (en) *	1993-11-23	1994-01-12	Merck Sharp & Dohme	Therapeutic agents
US5771890A (en) *	1994-06-24	1998-06-30	Cygnus, Inc.	Device and method for sampling of substances using alternating polarity
AU2944995A (en)	1994-06-24	1996-01-19	Cygnus, Inc.	Iontophoretic sampling device and method
AUPN814496A0 (en)	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
DE19814084B4 (de)	1998-03-30	2005-12-22	Lts Lohmann Therapie-Systeme Ag	D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AUPQ969800A0 (en) *	2000-08-28	2000-09-21	Fujisawa Pharmaceutical Co., Ltd.	Pyrazolopyridine compound and pharmaceutical use thereof
EP1344522A1 (en)	2001-05-08	2003-09-17	Schwarz Pharma Ag	Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
FR2829028B1 (fr) *	2001-08-29	2004-12-17	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HU227543B1 (en) *	2001-09-28	2011-08-29	Richter Gedeon Nyrt	N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
FR2834212B1 (fr) *	2001-12-27	2004-07-09	Besins Int Belgique	Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
EP1494664A2 (en) *	2002-04-18	2005-01-12	Pharmacia Corporation	Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
WO2004039320A2 (en) *	2002-10-25	2004-05-13	Collegium Pharmaceutical, Inc.	STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF
US9102726B2 (en) *	2002-12-04	2015-08-11	Argos Therapeutics, Inc.	Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10334188B4 (de)	2003-07-26	2007-07-05	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung von Depressionen
US20050032873A1 (en) *	2003-07-30	2005-02-10	Wyeth	3-Amino chroman and 2-amino tetralin derivatives
DE10359528A1 (de)	2003-12-18	2005-07-28	Schwarz Pharma Ag	(S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en)	2003-12-23	2005-06-29	Schwarz Pharma Ag	Intranasal formulation of rotigotine
EP1708706A1 (en) *	2004-01-22	2006-10-11	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
CA2568850A1 (en)	2004-08-02	2006-02-16	Schwarz Pharma Ag	Indolizine carboxamides and the aza and diaza derivatives thereof
DE102004054634A1 (de)	2004-11-12	2006-05-18	Schwarz Pharma Ag	Azaindolcarboxamide

2003
- 2003-12-23 EP EP03029680A patent/EP1547592A1/en not_active Withdrawn
2004
- 2004-12-22 DK DK04804221T patent/DK1605932T3/da active
- 2004-12-22 JP JP2006508291A patent/JP4430067B2/ja not_active Expired - Fee Related
- 2004-12-22 UA UAA200508587A patent/UA79196C2/uk unknown
- 2004-12-22 DE DE602004000982T patent/DE602004000982T2/de not_active Expired - Lifetime
- 2004-12-22 EA EA200501159A patent/EA008005B1/ru not_active IP Right Cessation
- 2004-12-22 ES ES04804221T patent/ES2262122T3/es not_active Expired - Lifetime
- 2004-12-22 EP EP04804221A patent/EP1605932B1/en not_active Expired - Lifetime
- 2004-12-22 KR KR1020057017173A patent/KR100718760B1/ko not_active Expired - Fee Related
- 2004-12-22 US US10/545,530 patent/US7683040B2/en not_active Expired - Fee Related
- 2004-12-22 BR BRPI0407845-4A patent/BRPI0407845A/pt not_active IP Right Cessation
- 2004-12-22 HR HR20060240T patent/HRP20060240T3/xx unknown
- 2004-12-22 CA CA002516400A patent/CA2516400C/en not_active Expired - Fee Related
- 2004-12-22 AT AT04804221T patent/ATE326961T1/de active
- 2004-12-22 PT PT04804221T patent/PT1605932E/pt unknown
- 2004-12-22 NZ NZ541875A patent/NZ541875A/en unknown
- 2004-12-22 CN CNB2004800109827A patent/CN100374112C/zh not_active Expired - Fee Related
- 2004-12-22 MX MXPA05008909A patent/MXPA05008909A/es active IP Right Grant
- 2004-12-22 PL PL04804221T patent/PL1605932T3/pl unknown
- 2004-12-22 AU AU2004308641A patent/AU2004308641B2/en not_active Ceased
- 2004-12-22 SI SI200430027T patent/SI1605932T1/sl unknown
- 2004-12-22 RS YUP-2006/0653A patent/RS50534B/sr unknown
- 2004-12-22 WO PCT/EP2004/014626 patent/WO2005063236A1/en not_active Ceased
2005
- 2005-08-16 IL IL170297A patent/IL170297A/en not_active IP Right Cessation
- 2005-08-16 ZA ZA200506550A patent/ZA200506550B/en unknown
- 2005-08-30 NO NO20054018A patent/NO20054018L/no not_active Application Discontinuation
2006
- 2006-05-26 IS IS8487A patent/IS2310B/is unknown
- 2006-08-09 CY CY20061101113T patent/CY1105131T1/el unknown

Also Published As

Publication number	Publication date
NZ541875A (en)	2008-08-29
BRPI0407845A (pt)	2006-02-14
IS8487A (is)	2006-05-26
WO2005063236A1 (en)	2005-07-14
RS50534B (sr)	2010-05-07
CY1105131T1 (el)	2009-11-04
CN1777422A (zh)	2006-05-24
CA2516400A1 (en)	2005-07-14
EA008005B1 (ru)	2007-02-27
ATE326961T1 (de)	2006-06-15
DE602004000982T2 (de)	2007-05-10
AU2004308641B2 (en)	2006-10-26
PL1605932T3 (pl)	2006-09-29
JP4430067B2 (ja)	2010-03-10
JP2006526004A (ja)	2006-11-16
HK1083596A1 (en)	2006-07-07
DE602004000982D1 (de)	2006-06-29
SI1605932T1 (sl)	2006-08-31
KR100718760B1 (ko)	2007-05-15
PT1605932E (pt)	2006-08-31
IL170297A (en)	2010-06-30
EP1605932B1 (en)	2006-05-24
CN100374112C (zh)	2008-03-12
UA79196C2 (en)	2007-05-25
ZA200506550B (en)	2006-05-31
DK1605932T3 (da)	2006-09-18
IS2310B (is)	2007-11-15
ES2262122T3 (es)	2006-11-16
KR20060040578A (ko)	2006-05-10
US20070191308A1 (en)	2007-08-16
HRP20060240T3 (hr)	2007-05-31
AU2004308641A1 (en)	2005-07-14
EA200501159A1 (ru)	2006-02-24
US7683040B2 (en)	2010-03-23
CA2516400C (en)	2009-10-27
MXPA05008909A (es)	2005-10-05
EP1547592A1 (en)	2005-06-29
EP1605932A1 (en)	2005-12-21

Publication	Publication Date	Title
NO20054018L (no)	2005-08-30	Intranasal formulering av rotigotin
NO20061840L (no)	2006-06-26	Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme
CY1112981T1 (el)	2016-04-13	Μεθοδος και συνθεση για την αγωγη της ρινιτιδας
NO20080164L (no)	2008-03-14	N-(pyridin-2-yl)-sulfonamidderivater
NO20012921L (no)	2001-06-14	Fenylglycin-derivater
DK1178958T3 (da)	2004-06-21	N-cyanomethylamider som proteaseinhibitorer
NO20042161L (no)	2004-08-17	Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NO20045281L (no)	2005-02-01	Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer
BR0210139A (pt)	2004-06-08	Composições farmacêuticas
CY1110906T1 (el)	2015-06-10	Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
NO20040356L (no)	2004-03-19	Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
EP1539122A4 (en)	2010-03-10	PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS
BR0209020A (pt)	2004-08-10	Composição farmacêutica de polialilamina
SE0101932D0 (sv)	2001-05-31	Pharmaceutical combinations
NO20062051L (no)	2006-07-25	Farmasoytisk virkestoffinneholdende formulering med belegg
PT1556371E (pt)	2006-09-29	Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
ATE417617T1 (de)	2009-01-15	Mittel zur steurung der expression von il-12
ATE357212T1 (de)	2007-04-15	Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
AR031649A1 (es)	2003-09-24	Composicion farmaceutica de dronedarona para administracion parenteral
NO20061702L (no)	2006-06-19	Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
HUP0202324A2 (hu)	2002-12-28	Prukaloprid orális oldat
NO20055367L (no)	2005-11-14	Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
EP1362590A8 (en)	2004-02-25	Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
NO20054346L (no)	2005-11-04	Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
ATE299027T1 (de)	2005-07-15	Verwendung von übersulfatierten polysacchariden als hiv-hemmer

Legal Events

Date	Code	Title	Description
2012-07-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application